Rafael Holdings Inc. manufactures metabolic oncology drugs to treat cancer. The company's product pipeline consists of CPI-613, CPI-618, CPI-1826 and CPI-3220 which are in clinical stages. Rafael Holdings Inc. is based in Newark, United States.
| Revenue (Most Recent Fiscal Year) | $0.92M |
| Net Income (Most Recent Fiscal Year) | $-30.52M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 56.35 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.79 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2988.48% |
| Net Margin (Trailing 12 Months) | -2846.60% |
| Return on Equity (Trailing 12 Months) | -37.27% |
| Return on Assets (Trailing 12 Months) | -31.02% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.44 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.41 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.29 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.91 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.79 |
| Exchange | NYSE |
| Sector | Real Estate |
| Industry | Real Estate Services |
| Common Shares Outstanding | 52.01M |
| Free Float | 34.90M |
| Market Capitalization | $65.54M |
| Average Volume (Last 20 Days) | 0.05M |
| Beta (Past 60 Months) | 0.51 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 32.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 11.30% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |